AstraZeneca & Bristol Myers Squibb in merger talks per Financial Times. AZ worth ~$265B, BMS ~$133B. Deal may involve stock & cash; talks may not lead to deal.
AstraZeneca is in talks with Bristol Myers Squibb about a merger that would be one of the industry’s largest ever, according to a report Sunday …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger - AstraZeneca (NYSE:AZN)
AstraZeneca in talks over £300bn mega-merger with US rival – reports
Pharma giants AstraZeneca and Bristol-Myers in reported merger talks
AstraZeneca, BMS discuss $400B pharma mega-deal
AstraZeneca share prices drop amid £300bn mega-merger talks with US rival
AstraZeneca said to have explored Bristol Myers merger | Fortune
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus - Bristol-Myers
UK's AstraZeneca eyeing $400b merger, report says
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
AstraZeneca Held Talks to Combine With Bristol Myers Squibb, FT Says, Citing Sources
